US Pharmaceutical Drug Delivery Market

The report "US Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injectable, Topical (Cream, Transdermal, Suppositories), Ocular, Nasal, Transmucosal, Implantable], Application (Cancer, Diabetes), Care Setting - Forecast to 2031" is projected to grow from USD 0.94 billion in 2026 and to reach USD 1.24 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast period.

Browse 380 market data Tables and 65 Figures spread through 400 Pages and in-depth TOC on "US Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injectable, Topical (Cream, Transdermal, Suppositories), Ocular, Nasal, Transmucosal, Implantable], Application (Cancer, Diabetes), Care Setting - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/us-pharmaceutical-drug-delivery-market-111487208.html

One of the primary factors driving the expansion of the US pharmaceutical drug delivery market is the increasing prevalence of chronic diseases, the growing adoption of biologics and complex treatments, and the rising trend towards more convenient and self-administered medications.

The growing prevalence of chronic conditions highlights the need for modern drug delivery systems, such as lipid nanoparticles, autoinjectors, inhalers, transdermal patches, and controlled-release formulations. These systems are essential for supporting advanced therapies, including mRNA-based treatments, cell & gene therapies, as well as the application of peptides and other large-molecule drugs. These technologies are tailored to secure drugs during their transit, to make doses precise and efficient, and to eventually provide patients with better health effects.

Despite this, the market still encounters some challenges related to the very high cost of developing and manufacturing intricate drug-device combination products and high-end formulations. The technology used to deliver these drugs goes through a very stringent quality control process and requires specialized materials and sophisticated device technologies, which, in turn, make research & development longer and more expensive. Meanwhile, the approval process for combination products has become even more rigorous due to the increased testing requirements for safety, usability, and device performance.

“Based on route of administration, the injectable drug delivery segment is expected to grow at the highest CAGR during the forecast period.”

In the US pharmaceutical drug delivery market, the injectable drug delivery segment is expected to witness rapid growth, mainly due to the fast-paced development of biologics, biosimilars, peptide therapies, monoclonal antibodies, and mRNA-based treatments. These therapies almost entirely depend on parenteral routes due to their poor oral bioavailability and sensitivity to gastrointestinal tract degradation.

Market growth is also supported by the development of new technologies for formulation and device engineering. Innovations such as autoinjectors, prefilled syringes, needle safety systems, depot injections, and on-body wearable injectors improve dosing accuracy, reduce contamination risks, and enhance patient comfort.

“The cancer segment is expected to register the highest CAGR in the US pharmaceutical drug delivery market during the forecast period.”

The cancer segment is one of the fastest-growing indication segments in the US pharmaceutical drug delivery market. Growth in this market segment is mainly driven by several factors, including the increasing incidence of cancer, the growing acceptance of targeted therapies, and the implementation of personalized medicine practices. Cancer treatments often involve a complex and diverse use of biologics, monoclonal antibodies, antibody-drug conjugates, and chemotherapies. These require careful and controlled delivery to maximize effectiveness while minimizing systemic toxicity. Recent advancements in delivery systems have introduced various methods, including injectable, implantable, and localized options such as long-acting depots, on-body injectors, nanoparticle carriers, and liposomal formulations. These innovations allow for greater concentrations of therapeutics to be delivered directly to tumors, thereby reducing side effects.

“Based on care setting, the home care settings segment is expected to witness the highest CAGR in the US pharmaceutical drug delivery market during the forecast period.”

The home care settings segment is the fastest-growing segment in the US pharmaceutical drug delivery market. This trend is caused by the shift from hospital-centered care models to outpatient and home treatment models. The growing use of self-administration devices is due to factors such as rising healthcare costs, patient preference for convenience, and the expansion of telemedicine. These devices include various automated technologies, such as autoinjectors, wearable injectors, on-body delivery systems, prefilled syringes, and connected smart devices that enable real-time monitoring of medication adherence. Home care delivery plays a crucial role in managing chronic conditions like diabetes, cancer, autoimmune disorders, and cardiovascular diseases. For these patients, consistent dosing and long-term therapy would otherwise require frequent visits to clinics.

Key Market Players

Some of the prominent players in the US pharmaceutical drug delivery market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), F. Hoffmann-La Roche (Switzerland), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), Amgen, Inc. (US), AbbVie Inc. (US), Gilead Sciences, Inc. (US), Eli Lilly and Company (US), Bristol-Myers Squibb (US), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Catalent Pharma Solutions (US), and Novartis (Switzerland).

Don’t miss out on business opportunities in US Pharmaceutical Drug Delivery Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/